·
·
Thursday, 8 October 2026dailybeirut.com
Health
A small trial suggests structured post-treatment support may reduce weight regain after stopping GLP-1 receptor agonists, though results are preliminary.
A preliminary study indicates that organized support following the cessation of obesity treatment may help limit weight regain during the first few months. However, the findings do not offer a guaranteed method to prevent rebound, nor do they prove that mobile applications or specialized meal plans can substitute for medication.
The research, published in the journal "Obesity Science & Practice," focused on adults who had lost weight using drugs from the glucagon-like peptide-1 (GLP-1) receptor agonist class. The trial included 39 participants randomly assigned to three distinct groups: 14 received usual care, 12 were provided with a subscription to a health support application, and 13 followed medically designed meal plans. Follow-up lasted four months, beginning immediately after the participants stopped their treatment.
The significance of this inquiry lies in the varied reasons patients might discontinue therapy, including cost, insurance coverage limitations, side effects, or personal preferences. Consequently, individuals may reach the post-medication phase without having established a clear plan for managing their weight afterward.
Statistical estimates from the study showed that body weight increased by 10.75 percent in the usual care group during the follow-up period. In contrast, the application group experienced a 3.60 percent increase, while the medically designed meals group saw a 3.58 percent rise.
These percentages represent the weight gain relative to body weight at the start of the follow-up after stopping treatment, rather than the proportion of previously lost kilograms regained. Furthermore, these figures are group-level estimates and do not imply that every individual participant gained the same amount of weight.
The primary conclusion is that both support groups experienced less weight gain than the control group, but neither maintained stable weight without change on average. Additionally, the similarity between the percentage increases in the app and meal groups does not confirm that the two interventions are equally effective.
The trial did not reveal statistically significant differences among the groups regarding assessments of diet quality, perceived health, adherence, or satisfaction. The sample size remains small and the follow-up period short, meaning the results are insufficient to determine what will happen after one year or more, or to identify the optimal option for each patient.
It is also inappropriate to generalize these findings to any commercial application or meal system. The experiment tested specific interventions, and its results require larger and longer studies before they can be converted into broad recommendations.
For users, addressing this stage begins with discussing the decision to stop treatment with a physician. This conversation should cover the reason for discontinuation, current health status, a plan for weight monitoring, and available treatment options.
Guidelines from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases suggest that weight management may combine appropriate nutrition, physical activity, specialized support, and regular monitoring. Certain medications may also be used to help maintain lost weight, subject to medical evaluation.
Follow-up can include regularly recording weight, reviewing eating patterns and activity levels, and agreeing on a date for reassessment if weight gain begins, rather than waiting until the increase becomes substantial. Decisions to resume medication, adjust dosage, or select alternative treatments are medical judgments that cannot be determined solely by scale readings.
The study highlights a phase that warrants planning from the onset of treatment: losing weight is a significant achievement, but maintaining it requires continuous monitoring, even after the final dose.
